Bank Of New York Mellon Corp Leap Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.42 - $9.18 $14,902 - $325,733	35,483 New	35,483 $15,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $1,431 - $2,847	-1,491 Reduced 4.03%	35,483 $41,000
Q1 2021 May 13, 2021	SELL	$1.82 - $3.01 $6,912 - $11,431	-3,798 Reduced 9.32%	36,974 $70,000
Q4 2020 Feb 09, 2021	SELL	$1.49 - $2.37 $31,516 - $50,130	-21,152 Reduced 34.16%	40,772 $91,000
Q3 2019 Nov 07, 2019	BUY	$1.17 - $2.36 $45,191 - $91,155	38,625 Added 165.78%	61,924 $72,000
Q2 2019 Aug 12, 2019	BUY	$1.36 - $2.07 $31,686 - $48,228	23,299 New	23,299 $42,000
Q1 2019 May 14, 2019	SELL	$1.39 - $3.07 $14,786 - $32,658	-10,638 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$1.92 - $7.94 $20,424 - $84,465	10,638 New	10,638 $21,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $344M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.